Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3

被引:54
作者
Yue, EW [1 ]
Higley, CA [1 ]
DiMeo, SV [1 ]
Carini, DJ [1 ]
Nugiel, DA [1 ]
Benware, C [1 ]
Benfield, PA [1 ]
Burton, CR [1 ]
Cox, S [1 ]
Grafstrom, RH [1 ]
Sharp, DM [1 ]
Sisk, LM [1 ]
Boylan, JF [1 ]
Muckelbauer, JK [1 ]
Smallwood, AM [1 ]
Chen, HY [1 ]
Chang, CH [1 ]
Seitz, SP [1 ]
Trainor, GL [1 ]
机构
[1] Bristol Myers Squibb Co, Expt Stn, Wilmington, DE 19880 USA
关键词
D O I
10.1021/jm0201722
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The identification of indeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin-dependent kinases (CDKs) has led to the discovery of a series of novel and potent compounds. Herein, we report the effects of substitutions at C3 of the indeno[1,2-c]pyrazol-4-one core with alkyls, heterocycles, and substituted phenyls. Substitutions at the para position of the phenyl ring at C3 were generally well-tolerated; however, larger groups were generally inactive. For alkyls directly attached to C3, longer chain substituents were not tolerated; however, shorter alkyl groups and cyclic alkyls were acceptable. In general, the heterocycles at C3 gave the most potent analogues. One such heterocycle, 24j, was examined in detail and was determined to have a biological profile consistent with CDK inhibition. An X-ray crystal structure of one of the alkyl compounds, 13% complexed with CDK2 was determined and showed the inhibitor residing in the adenosine 5'-triphosphate pocket of the enzyme.
引用
收藏
页码:5233 / 5248
页数:16
相关论文
共 46 条
[1]   Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases [J].
Barvian, M ;
Boschelli, DH ;
Cossrow, J ;
Dobrusin, E ;
Fattaey, A ;
Fritsch, A ;
Fry, D ;
Harvey, P ;
Keller, P ;
Garrett, M ;
La, F ;
Leopold, W ;
McNamara, D ;
Quin, M ;
Trumpp-Kallmeyer, S ;
Toogood, P ;
Wu, ZP ;
Zhang, EL .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (24) :4606-4616
[2]  
BENFIELD SP, 1999, 218 ACS NAT M NEW OR
[3]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[4]   Cell cycle molecular targets in novel anticancer drug discovery [J].
Buolamwini, JK .
CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (04) :379-392
[5]  
Carlson BA, 1996, CANCER RES, V56, P2973
[6]  
CZECH J, 1995, INT J ONCOL, V6, P31
[7]   RETRACTED: Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors (Retracted Article. See vol 298, pg 2327, 2002) [J].
Davis, ST ;
Benson, BG ;
Bramson, HN ;
Chapman, DE ;
Dickerson, SH ;
Dold, KM ;
Eberwein, DJ ;
Edelstein, M ;
Frye, SV ;
Gampe, RT ;
Griffin, RJ ;
Harris, PA ;
Hassell, AM ;
Holmes, WD ;
Hunter, RN ;
Knick, VB ;
Lackey, K ;
Lovejoy, B ;
Luzzio, MJ ;
Murray, D ;
Parker, P ;
Rocque, WJ ;
Shewchuk, L ;
Veal, JM ;
Walker, DH ;
Kuyper, LF .
SCIENCE, 2001, 291 (5501) :134-137
[8]   Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine [J].
DeAzevedo, WF ;
Leclerc, S ;
Meijer, L ;
Havlicek, L ;
Strnad, M ;
Kim, SH .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2) :518-526
[9]   CRYSTAL-STRUCTURE OF CYCLIN-DEPENDENT KINASE-2 [J].
DEBONDT, HL ;
ROSENBLATT, J ;
JANCARIK, J ;
JONES, HD ;
MORGAN, DO ;
KIM, SH .
NATURE, 1993, 363 (6430) :595-602
[10]   Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717 [J].
Dreyer, MK ;
Borcherding, DR ;
Dumont, JA ;
Peet, NP ;
Tsay, JT ;
Wright, PS ;
Bitonti, AJ ;
Shen, J ;
Kim, SH .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (04) :524-530